Sign inJoin waitlistJoin the waitlist

Jason Westin

Physician · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2008–2011
University of North Carolina School of Medicine
2002–2005
University of Florida College of Medicine
1998–2002

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2019 · 3,379 citations
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations

Sattva Neelapu
104 papers
Loretta Nastoupil
101 papers · 12 as a fellow
Luis Fayad
93 papers
NF
Nathan Fowler
68 papers
Christopher Flowers
59 papers
Sairah Ahmed
59 papers
Paolo Strati
57 papers
Fredrick Hagemeister
55 papers
FS
Felipe Samaniego
48 papers
Hun Lee
48 papers · 3 as a resident
Ranjit Nair
47 papers
Maria Rodriguez
46 papers

Clinical trials

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2027
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2027
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
Principal investigator · Active not recruiting
M.D. Anderson Cancer Center
2022–2027
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027